{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:29:34Z","timestamp":1787318974297,"version":"build-2736575974"},"reference-count":42,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Durvalumab consolidation after chemoradiotherapy (CRT) is a standard treatment for locally advanced non-small cell lung cancer (NSCLC). However, studies on immunological and nutritional markers to predict progression-free survival (PFS) and overall survival (OS) are inadequate. Systemic inflammation causes cancer cachexia and negatively affects immunotherapy efficacy, which also reflects survival outcomes. Patients and Methods: We retrospectively investigated 126 patients from seven institutes in Japan. Results: The modified Glasgow Prognostic Score (mGPS) values, before and after CRT, were the essential predictors among the evaluated indices. A systemic inflammation-based prognostic risk classification was created by combining mGPS values before CRT, and C-reactive protein (CRP) levels after CRT, to distinguish tumor-derived inflammation from CRT-induced inflammation. Patients were classified into high-risk (n = 31) and low-risk (n = 95) groups, and the high-risk group had a significantly shorter median PFS of 7.2 months and an OS of 19.6 months compared with the low-risk group. The hazard ratios for PFS and OS were 2.47 (95% confidence interval [CI]: 1.46\u20134.19, p &lt; 0.001) and 3.62 (95% CI: 1.79\u20137.33, p &lt; 0.001), respectively. This association was also observed in the subgroup with programmed cell death ligand 1 expression of \u226550%, but not in the &lt;50% subgroup. Furthermore, durvalumab discontinuation was observed more frequently in the high-risk group than in the low-risk group. Conclusion: Combining pre-CRT mGPS values with post-CRT CRP levels in patients with locally advanced NSCLC helps to predict the PFS and OS of durvalumab consolidation after CRT.<\/jats:p>","DOI":"10.3390\/cancers15174358","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T08:45:31Z","timestamp":1693557931000},"page":"4358","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7826-4466","authenticated-orcid":false,"given":"Keiko","family":"Tanimura","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto 602-8026, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8375-6940","authenticated-orcid":false,"given":"Takayuki","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto 602-8026, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3753-2110","authenticated-orcid":false,"given":"Akihiro","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto 602-8026, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Asahi General Hospital, Asahi 289-2511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Goda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto 605-0981, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7195-0770","authenticated-orcid":false,"given":"Shinsuke","family":"Shiotsu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto 605-0981, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototaka","family":"Fukui","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Uji-Tokushukai Medical Center, Uji 611-0041, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Chihara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Uji-Tokushukai Medical Center, Uji 611-0041, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoaki","family":"Uryu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Yao Tokushukai General Hospital, Yao 581-0011, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Takei","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Katayama","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1638-5027","authenticated-orcid":false,"given":"Makoto","family":"Hibino","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Shonan Fujisawa Tokushukai Hospital, Fujisawa 251-0041, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6945-281X","authenticated-orcid":false,"given":"Tadaaki","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7723-8960","authenticated-orcid":false,"given":"Koichi","family":"Takayama","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e2249591","DOI":"10.1001\/jamanetworkopen.2022.49591","article-title":"Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patents with Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiation and Durvalumab","volume":"6","author":"Lebow","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/imr.12614","article-title":"IL-1 and IL-1 regulatory pathways in cancer progression and therapy","volume":"281","author":"Mantovani","year":"2018","journal-title":"Immunol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.4049\/jimmunol.1202769","article-title":"The Role of IL-1\u03b2 in the Early Tumor Cell\u2013Induced Angiogenic Response","volume":"190","author":"Carmi","year":"2013","journal-title":"J. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1111\/cas.13332","article-title":"Interleukin-6\/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy","volume":"108","author":"Kitamura","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: An international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lungcan.2011.09.012","article-title":"Pre-cachexia in patients with stages I\u2013III non-small cell lung cancer: Systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system","volume":"76","author":"Kamp","year":"2012","journal-title":"Lung Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/mus.21893","article-title":"CALPAIN activity is increased in skeletal muscle from gastric cancer patients with no or minimal weight loss","volume":"43","author":"Smith","year":"2011","journal-title":"Muscle Nerve"},{"key":"ref_11","first-page":"100020","article-title":"Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients with Advanced NSCLC","volume":"1","author":"Miyawaki","year":"2020","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1950411","DOI":"10.1080\/2162402X.2021.1950411","article-title":"Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: A retrospective study","volume":"10","author":"Morimoto","year":"2021","journal-title":"OncoImmunology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.01.013","article-title":"Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer","volume":"106","author":"Bagley","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","article-title":"Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors","volume":"12","author":"Valero","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Zhou, X., Du, Y., Huang, Z., Xu, J., Qiu, T., Wang, J., Wang, T., Zhu, W., and Liu, P. (2014). Prognostic Value of PLR in Various Cancers: A Meta-Analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0101119"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"23893","DOI":"10.1038\/srep23893","article-title":"Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: Evidence from 3430 patients","volume":"6","author":"Gu","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Frey, A., Martin, D., D\u2019cruz, L., Fokas, E., R\u00f6del, C., and Fleischmann, M. (2022). C-Reactive Protein to Albumin Ratio as Prognostic Marker in Locally Advanced Non-Small Cell Lung Cancer Treated with Chemoradiotherapy. Biomedicines, 10.","DOI":"10.3390\/biomedicines10030598"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1245\/s10434-014-4048-0","article-title":"The C-Reactive Protein\/Albumin Ratio, a Novel Inflammation-Based Prognostic Score, Predicts Outcomes in Patients with Hepatocellular Carcinoma","volume":"22","author":"Kinoshita","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100254","DOI":"10.1016\/j.esmoop.2021.100254","article-title":"Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer","volume":"6","author":"Mountzios","year":"2021","journal-title":"ESMO Open"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-14-0442","article-title":"Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma","volume":"20","author":"Hu","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2217\/imt-2022-0133","article-title":"Systemic immune\u2013inflammation index predicts prognosis of cancer immunotherapy: Systemic review and meta-analysis","volume":"14","author":"Tian","year":"2022","journal-title":"Immunotherapy"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1017\/S0029665108007131","article-title":"An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer","volume":"67","author":"Mcmillan","year":"2008","journal-title":"Proc. Nutr. Soc."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","article-title":"The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer","volume":"39","author":"Mcmillan","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/1759-7714.13426","article-title":"Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer","volume":"11","author":"Chu","year":"2020","journal-title":"Thorac. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1111\/1759-7714.14484","article-title":"Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapy","volume":"13","author":"Araki","year":"2022","journal-title":"Thorac. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.clnu.2019.07.002","article-title":"Clinical utility of the modified Glasgow Prognostic Score to classify cachexia in patients with advanced cancer in palliative care","volume":"39","author":"Silva","year":"2020","journal-title":"Clin. Nutr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.lungcan.2019.07.027","article-title":"Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy","volume":"136","author":"Choe","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1038\/onc.2008.271","article-title":"The tumor microenvironment and its role in promoting tumor growth","volume":"27","author":"Whiteside","year":"2008","journal-title":"Oncogene"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3389\/fimmu.2020.00784","article-title":"The tumor microenvironment in the response to immune checkpoint blockade therapies","volume":"11","author":"Petitprez","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1038\/s41467-017-02358-7","article-title":"TNFalpha blockade overcomes resistance to anti-PD-1 in experimental melanoma","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1073\/pnas.1812266115","article-title":"Blocking IL-1\u03b2 reverses the immunosuppression in mouse breast cancer and synergizes with anti\u2013PD-1 for tumor abrogation","volume":"116","author":"Kaplanov","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.cmet.2016.10.010","article-title":"Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity","volume":"24","author":"Flint","year":"2016","journal-title":"Cell Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"80506","DOI":"10.18632\/oncotarget.19193","article-title":"Radiation alters PD-L1\/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK\/Erk signaling pathway","volume":"8","author":"Shen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.imlet.2017.02.006","article-title":"Inflammatory cytokines IL-17 and TNF-\u03b1 up-regulate PD-L1 expression in human prostate and colon cancer cells","volume":"184","author":"Wang","year":"2017","journal-title":"Immunol. Lett."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.clnu.2019.02.029","article-title":"Low muscle mass is associated with early termination of chemotherapy related to toxicity in patients with head and neck cancer","volume":"39","author":"Sealy","year":"2020","journal-title":"Clin. Nutr."},{"key":"ref_40","first-page":"876","article-title":"Alterations of ghrelin with weights and correlation among ghrelin, cytokine and survival in patients receiving chemoradiotherapy for gastrointestinal cancers","volume":"8","author":"Karaca","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1002\/cncr.27430","article-title":"Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: A prospective, randomized, placebo-controlled phase 2 study","volume":"118","author":"Hiura","year":"2012","journal-title":"Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/cncr.31128","article-title":"Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04)","volume":"124","author":"Katakami","year":"2018","journal-title":"Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/17\/4358\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:44:31Z","timestamp":1760129071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/17\/4358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":42,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["cancers15174358"],"URL":"https:\/\/doi.org\/10.3390\/cancers15174358","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}